FDA Approves At-Home Nasal Flu Vaccine for Next Year

The new FluMist nasal spray allows self-administration and will be available online starting next fall.

FluMist, developed by AstraZeneca, is the first flu vaccine approved for self-administration at home.
The nasal spray vaccine will be available for people aged 2 to 49, with adults able to administer it to themselves and caregivers to children.
To obtain the vaccine, users will need to complete an online screening and eligibility assessment through a new pharmacy website.
The FDA approval aims to increase convenience, flexibility, and accessibility for flu vaccinations.
The vaccine's cost is currently estimated at $35 to $45 per dose, though insurance coverage may reduce this price.